William B. J. Lehmann Jr., M.B.A., J.D., MBA
Net Worth
Last updated:
What is William B. J. Lehmann Jr., M.B.A., J.D., MBA net worth?
The estimated net worth of Mr. William B. J. Lehmann Jr., M.B.A., J.D., MBA is at least $10,600,677 as of 15 Dec 2021. He owns shares worth $12,253 as insider, has earned $983,624 from insider trading and has received compensation worth at least $9,604,800 in Athersys, Inc..
What is the salary of William B. J. Lehmann Jr., M.B.A., J.D., MBA?
Mr. William B. J. Lehmann Jr., M.B.A., J.D., MBA salary is $533,600 per year as Pres, Chief Operating Officer, Sec. & Interim Chief Executive Officer in Athersys, Inc..
How old is William B. J. Lehmann Jr., M.B.A., J.D., MBA?
Mr. William B. J. Lehmann Jr., M.B.A., J.D., MBA is 59 years old, born in 1966.
What stocks does William B. J. Lehmann Jr., M.B.A., J.D., MBA currently own?
As insider, Mr. William B. J. Lehmann Jr., M.B.A., J.D., MBA owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Athersys, Inc. (ATHX) | Pres, Chief Operating Officer, Sec. & Interim Chief Executive Officer | 471,287 | $0.03 | $12,253 |
What does Athersys, Inc. do?
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
William B. J. Lehmann Jr., M.B.A., J.D., MBA insider trading
Athersys, Inc.
Mr. William B. J. Lehmann Jr., M.B.A., J.D., MBA has made 43 insider trades between 2007-2021, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 30,000 units of ATHX stock on 19 Jun 2018. As of 15 Dec 2021 he still owns at least 471,287 units of ATHX stock.
Athersys key executives
Athersys, Inc. executives and other stock owners filed with the SEC:
- Dr. John J. Harrington (58) Co-Founder, Chief Scientific Officer, Executive Vice President & Director
- Mr. Ivor Macleod CPA, M.B.A. (63) Chief Financial Officer & Principal Accounting Officer
- Mr. William B. J. Lehmann Jr., M.B.A., J.D., MBA (59) Pres, Chief Operating Officer, Sec. & Interim Chief Executive Officer